Drugs News and Research

RSS

Danish scientists discover what controls ADAM17 enzyme that aids growth of cancer tumours

Researchers from the University of Copenhagen have discovered what regulates an enzyme that is central to the growth of cancer tumours. This could be of great value to future cancer treatment.

30 Jun 2015

PharmaMar begins PM1183 phase III study in patients with platinum-resistant ovarian cancer

PharmaMar announced today the start of a phase III study for the anticancer agent PM1183 in patients with platinum-resistant ovarian cancer (PROC). Once study objectives are met, the CORAIL trial (NCT02421588) will be used to support the regulatory filing of PM1183 as treatment for this indication.

30 Jun 2015

New technology can detect illegal drugs from a single fingerprint

An innovative technology pioneered by Sheffield Hallam University academics can detect the presence of a range of illegal and designer drugs from a single fingerprint, which could be a valuable new tool in bringing drug dealers and other criminals to justice.

From Sheffield Hallam University 29 Jun 2015

Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

Inhibikase Therapeutics, Inc. announces the receipt of a Phase II SBIR grant in the amount of $1.54 million dollars from the U.S. National Institutes of Health to advance its novel Re-engineering with Metabolism Preserved (RAMP) medicinal chemistry program.

29 Jun 2015

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

SillaJen, Inc., a private clinical-stage biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, today announced a publication of data demonstrating that in a Phase Ib trial of Pexa-Vec, patients received multiple bi-weekly doses of its lead product Pexa-Vec, representing the first report of multiple intravenous administrations of an oncolytic vaccinia.

29 Jun 2015

Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Tris Pharma, Inc. today announced that it has entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare.

29 Jun 2015

Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

According to analysis from business intelligence provider GBI Research - Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2020 - the value of the global Glioblastoma Multiforme (GBM) treatment market will expand at a rapid Compound Annual Growth Rate (CAGR) of 10.9%, from $301 million in 2013 to $623 million by 2020.

29 Jun 2015

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, today reported further progress in its continuing preclinical program of its CF602 drug candidate as the Company prepares to file an investigational new drug (IND) application with the U.S. Food and Drug Administration to allow the initiation of a Phase I clinical study.

29 Jun 2015

Cosmederm Bioscience expands TriCalm's line of anti-itch products to further benefit sufferers of itch

Cosmederm Bioscience, Inc. today announced the expansion of its itch-relief product line, TriCalm, with the new TriCalm Clinical Repair Cream and TriCalm Extra Strength Spray. Following the success of the company's initial product, TriCalm Hydrogel, these two new offerings strategically expand the brand's line of steroid-free, anti-itch products to further benefit sufferers of itch.

29 Jun 2015

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Spinifex Pharmaceuticals, Inc., a company focused on the development of new drugs for the treatment of chronic pain, today announces that it has agreed to the sale of Spinifex to Novartis International AG, for an upfront cash consideration of US$200 million plus undisclosed clinical development and regulatory milestone payments.

29 Jun 2015

Artemisinin and the fight against malaria: an interview with Dr. Robert Sebbag, Sanofi

Since 2014, more than 16 million anti-malarial treatments derived from the Sanofi patented process for semi-synthetic artemisinin have been supplied to endemic countries in Africa.

From Sanofi 28 Jun 2015

Two physician-scientists in search for better Alzheimer's disease treatment

Two of the nation's leading physician-scientists in the search to better understand and treat Alzheimer's disease - William Mobley, MD, PhD, and Michael Rafii, MD, PhD - have been named interim co-directors of the Alzheimer's Disease Cooperative Study (ADCS), a major initiative formed in 1991 as a cooperative agreement between the National Institute on Aging (NIA) and the University of California, San Diego.

27 Jun 2015

Adding tamper resistant properties to medications can help curb prescription drug abuse

Health Canada today published a Notice of Pre-Consultation in Canada Gazette, Part I, seeking stakeholder feedback on draft Tamper-Resistant Properties of Drugs Regulations.

27 Jun 2015

NIDA announces recipients of Avenir Award programs for HIV/AIDS, genetics or epigenetics research

The National Institute on Drug Abuse today announced the first six recipients of its two newly developed Avenir Award programs for HIV/AIDS and genetics or epigenetics research. The Avenir (meaning "future" in French) Awards support early stage investigators who propose highly innovative studies. The six scientists will each receive up to $300,000 per year for five years to support their research.

27 Jun 2015

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun a new Phase Ib/II clinical trial using a new immunotherapy treatment for patients with advanced kidney, non-small cell lung cancer, pancreatic cancer and colorectal carcinoma.

27 Jun 2015

Health Canada informs Canadians that eight unauthorized health products were seized from Better Bodies Supplements

Health Canada is informing Canadians that eight unauthorized health products (listed in the table below) were seized from Better Bodies Supplements, 118 Main Street North, in Airdrie, Alta.

27 Jun 2015

Study: High blood pressure linked to lower risk for Alzheimer's disease

A new study suggests that people with a genetic predisposition to high blood pressure have a lower risk for Alzheimer's disease.

27 Jun 2015

SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

In research published in Cancer Cell, Thomas Burris, Ph.D., chair of pharmacology and physiology at Saint Louis University, has, for the first time, found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.

26 Jun 2015

Caya contoured diaphragm to expand U.S. women's options for nonhormonal barrier contraception

With the launch of the Caya contoured diaphragm this June, women in the United States will have access to a method of contraception that is nonhormonal, has few side effects, and can be used for up to two years. Last fall, the United States Food and Drug Administration cleared the single-size Caya contoured diaphragm for marketing in the US, and now the diaphragm is available by prescription from healthcare providers.

26 Jun 2015

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Xencor, Inc., a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced updates on its lead product candidates, XmAb®5871 and XmAb®7195, and on its XmAb® bispecific oncology pipeline.

26 Jun 2015

Drugs News and Research

Danish scientists discover what controls ADAM17 enzyme that aids growth of cancer tumours

PharmaMar begins PM1183 phase III study in patients with platinum-resistant ovarian cancer

New technology can detect illegal drugs from a single fingerprint

Inhibikase Therapeutics receives Phase II SBIR grant to advance novel RAMP medicinal chemistry program

Clinical data demonstrates safe administration of Pexa-Vec in patients with metastatic colorectal cancer

Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Global GBM therapeutics market to expand at CAGR of 10.9% to $623 million by 2020

Can-Fite reports further progress in continuing preclinical program of CF602 sexual dysfunction drug

Cosmederm Bioscience expands TriCalm's line of anti-itch products to further benefit sufferers of itch

Spinifex Pharmaceuticals enters into agreement to be acquired by Novartis

Artemisinin and the fight against malaria: an interview with Dr. Robert Sebbag, Sanofi

Two physician-scientists in search for better Alzheimer's disease treatment

Adding tamper resistant properties to medications can help curb prescription drug abuse

NIDA announces recipients of Avenir Award programs for HIV/AIDS, genetics or epigenetics research

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Health Canada informs Canadians that eight unauthorized health products were seized from Better Bodies Supplements

Study: High blood pressure linked to lower risk for Alzheimer's disease

SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

Caya contoured diaphragm to expand U.S. women's options for nonhormonal barrier contraception

Xencor announces progress and expansion of proprietary pipeline of XmAb antibodies

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News